Checkmate Pharmaceuticals Inc. (CMPI): Price and Financial Metrics


Checkmate Pharmaceuticals Inc. (CMPI): $10.50

0.02 (+0.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CMPI Stock Price Chart Interactive Chart >

Price chart for CMPI

CMPI Price/Volume Stats

Current price $10.50 52-week high $10.50
Prev. close $10.48 52-week low $2.00
Day low $10.48 Volume 63,600
Day high $10.50 Avg. volume 142,261
50-day MA $7.30 Dividend yield N/A
200-day MA $4.60 Market Cap 231.40M

Checkmate Pharmaceuticals Inc. (CMPI) Company Bio


Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.


CMPI Latest News Stream


Event/Time News Detail
Loading, please wait...

CMPI Latest Social Stream


Loading social stream, please wait...

View Full CMPI Social Stream

Latest CMPI News From Around the Web

Below are the latest news stories about Checkmate Pharmaceuticals Inc that investors may wish to consider to help them evaluate CMPI as an investment opportunity.

Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight

Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist...

Benzinga | February 21, 2022

The Petri Dish: Syndax, Checkmate get new CEOs; Biogen stays in biosimilars game

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.

Yahoo | February 10, 2022

Checkmate Pharmaceuticals appoints Alan Bash as President, CEO

Checkmate Pharmaceuticals (CMPI) announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1, 2022

Seeking Alpha | February 9, 2022

Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO

Accomplished global biopharmaceutical executive with over 20 years of strategic and operational leadership at Bristol Myers SquibbCAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1

Yahoo | February 9, 2022

Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Jon Wigginton, M.D. to its Board of Directors (“Board”). “Jon is a well-respected physician-scientist and drug development expert. With his diverse background, he has driven numerous clinical stage immu

Yahoo | January 31, 2022

Read More 'CMPI' Stories Here

CMPI Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 190.06%
3-year N/A
5-year N/A
YTD 265.85%
2021 -80.33%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6619 seconds.